» Articles » PMID: 26079617

A Novel DNA Vaccine for Reduction of PRRSV-induced Negative Immunomodulatory Effects: A Proof of Concept

Overview
Journal Vaccine
Date 2015 Jun 17
PMID 26079617
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Viral-induced interleukin (IL)-10 and regulatory T lymphocytes (Tregs) are believed to play a major role in shaping the immunological and clinical outcomes following Porcine Reproductive and Respiratory Syndrome virus (PRRSV) infection. Recently, it has been shown that PRRSV nucleocapsid (N) protein can induce IL-10 production which is essential for induction of PRRSV-specific Tregs. We hypothesized that immunity to N protein should reduce PRRSV-induced negative immunomodulatory effects which will be essential for establishing proper anti-PRRSV immunity in infected pigs.

Objectives: To investigate the immunomodulatory effects of DNA vaccine encoding a linearized, truncated form of PRRSV-N protein (pORF7t) which was designed to preferentially induce cell-mediated immunity against PRRSV N protein.

Method: Immunomodulatory effects of the novel DNA vaccine were investigated in an experimental vaccinated-challenged model. In addition, long-term immunomodulatory effects of the DNA vaccine were investigated in vaccinated pigs kept at the PRRSV-positive environment until the end of the fattening period. Pigs were vaccinated either prior to or following natural PRRSV infection.

Result: The results indicated that pORF7t could modulate the anti-PRRSV immune responses and promote the control of viral replication in the vaccinated-challenged pigs. Immunized pigs exhibited increased numbers of PRRSV-specific activated CD4(+)CD25(+) lymphocytes, reduced numbers of PRRSV-specific Tregs, and rapid viral clearance following infection. In a long-term study, regardless of the time of vaccination, DNA vaccine could modulate the host immune responses, resulted in enhanced PRRSV-specific IFN-γ producing cells, and reduced numbers of PRRSV-specific Tregs, without evidence of enhanced antibody responses. No vaccine adverse reaction was observed throughout the study.

Conclusion: This study revealed the novel concept that PRRSV-specific immunity can be modulated by induction of cell-mediated immunity against the nucleocapsid protein. This concept could potentially benefit the development of PRRSV management and control strategies.

Citing Articles

Research progress on the N protein of porcine reproductive and respiratory syndrome virus.

Zheng Y, Li G, Luo Q, Sha H, Zhang H, Wang R Front Microbiol. 2024; 15:1391697.

PMID: 38741730 PMC: 11089252. DOI: 10.3389/fmicb.2024.1391697.


Porcine Reproductive and Respiratory Syndrome Modified Live Virus Vaccine: A "Leaky" Vaccine with Debatable Efficacy and Safety.

Zhou L, Ge X, Yang H Vaccines (Basel). 2021; 9(4).

PMID: 33918580 PMC: 8069561. DOI: 10.3390/vaccines9040362.


A DNA Prime Immuno-Potentiates a Modified Live Vaccine against the Porcine Reproductive and Respiratory Syndrome Virus but Does Not Improve Heterologous Protection.

Bernelin-Cottet C, Urien C, Fretaud M, Langevin C, Trus I, Jouneau L Viruses. 2019; 11(6).

PMID: 31242645 PMC: 6631340. DOI: 10.3390/v11060576.


Efficacy of a type 2 PRRSV modified live vaccine (PrimePac™ PRRS) against a Thai HP-PRRSV challenge.

Sirisereewan C, Woonwong Y, Arunorat J, Kedkovid R, Nedumpun T, Kesdangsakonwut S Trop Anim Health Prod. 2018; 50(7):1509-1518.

PMID: 29696456 DOI: 10.1007/s11250-018-1589-4.


Efficacy of live attenuated porcine reproductive and respiratory syndrome virus 2 strains to protect pigs from challenge with a heterologous Vietnamese PRRSV 2 field strain.

Sattler T, Pikalo J, Wodak E, Revilla-Fernandez S, Steinrigl A, Bago Z BMC Vet Res. 2018; 14(1):133.

PMID: 29673363 PMC: 5907707. DOI: 10.1186/s12917-018-1451-y.